The specialist drug discovery company has filed a PCT application covering its P140 treatment and the Type M patient profile linked to stronger response rates, as it continues talks toward a commercial deal in 2026.
ImmuPharma has appointed the GLP-certified CRO to validate bioanalytical methods supporting Kapiglucagon's nonclinical and Phase 1 clinical programs.
"We are pleased to select Thermo Fisher as DP CDMO for the Kapiglucagon program," said Dr Sébastien Goudreau
ImmuPharma has selected Bachem as the active pharmaceutical ingredient manufacturer for its Kapiglucagon diabetes candidate, marking a key chemistry, manufacturing and controls milestone ahead of IND-enabling work.
"ImmuPharma is entering a pivotal phase, focused on securing a commercial partnership for P140 in 2026 while continuing to develop its broader portfolio, with a key focus on fast tracking Kapiglucagon over the next two years," said Tim McCarthy, CEO and Chairman.
ImmuPharma has engaged tranScrip to prepare a pre‑IND meeting with the FDA and pursue a 505(b)(2) regulatory route for its Kapiglucagon diabetes prodrug.